XCNQIPOT
Market cap1mUSD
Apr 05, Last price
0.02CAD
Name
Isracann Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
101.23%
Revenues
0k
Net income
0k
P
CFO
0k
P
Profile
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany. The company was formerly known as Atlas Blockchain Group Inc. and changed its name to Isracann Biosciences Inc. in October 2019. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | 2015‑05 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 2,547 | ||||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,547) | ||||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,469) | ||||||||
Tax Rate | |||||||||
NOPAT | (1,078) | ||||||||
Net income | (4,693) -81.34% | ||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 130 | ||||||||
BB yield | -1.26% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 2,885 | ||||||||
Net debt | (214) | ||||||||
| Cash flow | |||||||||
Cash from operating activities | (1,755) | ||||||||
CAPEX | |||||||||
Cash from investing activities | (77) | ||||||||
Cash from financing activities | 130 | ||||||||
FCF | (523) | (466) | |||||||
| Balance | |||||||||
Cash | 214 | ||||||||
Long term investments | |||||||||
Excess cash | 214 | ||||||||
Stockholders' equity | 276 | ||||||||
Invested Capital | 2,961 | ||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 147,753 | ||||||||
Price | 0.07 -68.18% | ||||||||
Market cap | 10,343 -66.03% | ||||||||
EV | 10,241 | ||||||||
EBITDA | (2,506) | ||||||||
EV/EBITDA | |||||||||
Interest | 14 | ||||||||
Interest/NOPBT | |||||||||